financetom
Business
financetom
/
Business
/
Peloton Swings to Profit in Fiscal Q4, Revenue Falls; Fiscal 2026 Revenue Outlook Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Peloton Swings to Profit in Fiscal Q4, Revenue Falls; Fiscal 2026 Revenue Outlook Set
Aug 7, 2025 6:08 AM

08:51 AM EDT, 08/07/2025 (MT Newswires) -- Peloton Interactive ( PTON ) reported fiscal Q4 earnings Thursday of $0.05 per diluted share, swinging from a loss of $0.08 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.07.

Revenue for the quarter ended June 30 was $606.9 million, down from $643.6 million a year earlier.

Analysts polled by FactSet expected $580.2 million.

The company expects fiscal 2026 total revenue of $2.4 billion to $2.5 billion. Analysts surveyed by FactSet expect $2.42 billion.

Q1 total revenue is projected at $525.0 million to $545.0 million. Analysts polled by FactSet expect $555 million.

Shares of the company were up 11% in recent Thursday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
EXPLAINER-Family feud over Korea's zinc giant threatens to affect supply chain
EXPLAINER-Family feud over Korea's zinc giant threatens to affect supply chain
Oct 4, 2024
SEOUL, Oct 4 (Reuters) - Korea Zinc, the world's biggest refined zinc producer, has been embroiled in a bitter feud among founding families over control of its $12 billion zinc empire. The winner of the battle stands to control South Korea's significant player in a U.S.-led effort to reduce heavy reliance on China for key metals and materials used in...
Update: Summit Therapeutics Closes Phase 3 Lung Cancer Study Enrollment, Gets FDA Fast Track; Shares up Premarket
Update: Summit Therapeutics Closes Phase 3 Lung Cancer Study Enrollment, Gets FDA Fast Track; Shares up Premarket
Oct 4, 2024
05:03 AM EDT, 10/04/2024 (MT Newswires) -- (Updates with the stock move and FDA fast track in the headline and the last two paragraphs.) Summit Therapeutics ( SMMT ) said late Thursday that it completed enrollment in its late-stage HARMONi clinical trial from North America, Europe, and China, with topline data expected in mid-2025. The study is evaluating ivonescimab plus...
EU top court sides with activist Schrems in privacy dispute with Meta
EU top court sides with activist Schrems in privacy dispute with Meta
Oct 4, 2024
BRUSSELS (Reuters) - Europe's top court on Friday sided with Austrian privacy activist Max Schrems in his privacy dispute with Meta Platforms. Schrems had taken his grievance to an Austrian court, saying he had been targeted by advertisements directed at homosexuals as a result of Meta's personalised advertising based on processing of personal data. The court subsequently sought guidance from...
EU vote on Chinese EV tariffs inconclusive, leaving EU Commission to decide, EU sources says
EU vote on Chinese EV tariffs inconclusive, leaving EU Commission to decide, EU sources says
Oct 4, 2024
BRUSSELS, Oct 4 (Reuters) - European Union countries failed to vote clearly in favour or against tariffs of up to 45% on Chinese electric vehicles, leaving the European Commission to decide what to do, EU sources said on Friday. The EU executive could adopt the tariffs or could submit a new proposal if it wished to secure broader support among...
Copyright 2023-2026 - www.financetom.com All Rights Reserved